Rich Pharmaceuticals Inc (RCHA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Rich Pharmaceuticals Inc (RCHA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8304
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Rich Pharmaceuticals Inc (Rich Pharmaceuticals) is a biopharmaceutical company that offers discovery and development of therapies for the treatment of acute myelogenous leukemia (AML) in refractory patients. The company’s pipeline portfolio offers a lead drug candidate for the treatment of acute myeloid leukemia (AML). It also develops compounds acure myeloid lekemia and hodgkins lymphoma through phase clinical trials. Rich Pharmaceuticals compounds are also used for the treatment of Hodgkin’s lymphoma. The company offers administration of TPA and toxicity associated with TPA, predominately dyspnea, fever, chills, venous irritation and hematuria. It works in collaboration with non-profit institutes to develop technologies. Rich Pharmaceuticals is headquartered in Beverly Hills, California, the US.

Rich Pharmaceuticals Inc (RCHA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Rich Pharma Acquires Patents for Treatment of Hodgkin’s Lymphoma from Richard l. Chang and Imagic 12
Rich Pharma to Acquire Certain Assets from Imagic 13
Partnerships 14
Rich Pharma Enters into Agreement with Mega Bridge 14
Rich Pharma Partners with Theradex Systems 15
Rich Pharma Partners with CMIC Asia-Pacific 16
Rich Pharma Extends Agreement with Theradex Systems 17
Equity Offering 18
Rich Pharma Files Registration Statement for Public Offering of Shares 18
Rich Pharma to Raise up to USD2 Million in Private Placement of Shares 19
Rich Pharma to Raise USD2 Million in Private Placement of Shares 20
Rich Pharma to Raise USD4.5 Million in Private Placement of Common Stock 21
Rich Pharma Completes Public Offering Of Shares For US$0.4 Million 22
Rich Pharma Raises USD0.3 Million in Private Placement of Units 23
Rich Pharma Raises Funds in Private Placement of Units 24
Debt Offering 25
Rich Pharma Raises USD0.07 Million in Private Placement of 10% Notes 25
Rich Pharma Raises USD0.1 Million in Private Placement of 10% Notes 26
Rich Pharma Raises USD0.03 Million in Private Placement of 8% Notes 27
Rich Pharma Raises Funds through Private Placement of 8% Notes Due 2016 28
Rich Pharma Raises Funds through Private Placement of 8% Notes Due 2016 29
Rich Pharma Raises USD0.1 Million in Private Placement of 8% Notes Due 2016 30
Rich Pharma Raises Funds in Private Placement of 8% Notes 31
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 32
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 33
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 34
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 35
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 36
Rich Pharma Raises Funds in Private Placement of Notes Due 2015 37
Rich Pharma Raises USD0.5 Million in Private Placement of Notes 38
Rich Pharma Raises USD0.4 Million in Private Placement of Notes 39
Rich Pharmaceuticals Inc – Key Competitors 40
Rich Pharmaceuticals Inc – Key Employees 41
Rich Pharmaceuticals Inc – Locations And Subsidiaries 42
Head Office 42
Recent Developments 43
Financial Announcements 43
Apr 06, 2017: Rich Pharmaceuticals announces Industry Veteran to Join CannCodex 43
Corporate Communications 44
Apr 10, 2017: Rich Pharmaceuticals Welcomes New Board Member 44
Legal and Regulatory 45
Jun 08, 2017: Rich Pharmaceuticals Announces Institutional Review Board Submission 45
Other Significant Developments 46
May 31, 2017: Rich Pharmaceuticals Announces Clinical Site in Thailand 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rich Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Rich Pharma Acquires Patents for Treatment of Hodgkin's Lymphoma from Richard l. Chang and Imagic 12
Rich Pharma to Acquire Certain Assets from Imagic 13
Rich Pharma Enters into Agreement with Mega Bridge 14
Rich Pharma Partners with Theradex Systems 15
Rich Pharma Partners with CMIC Asia-Pacific 16
Rich Pharma Extends Agreement with Theradex Systems 17
Rich Pharma Files Registration Statement for Public Offering of Shares 18
Rich Pharma to Raise up to USD2 Million in Private Placement of Shares 19
Rich Pharma to Raise USD2 Million in Private Placement of Shares 20
Rich Pharma to Raise USD4.5 Million in Private Placement of Common Stock 21
Rich Pharma Completes Public Offering Of Shares For US$0.4 Million 22
Rich Pharma Raises USD0.3 Million in Private Placement of Units 23
Rich Pharma Raises Funds in Private Placement of Units 24
Rich Pharma Raises USD0.07 Million in Private Placement of 10% Notes 25
Rich Pharma Raises USD0.1 Million in Private Placement of 10% Notes 26
Rich Pharma Raises USD0.03 Million in Private Placement of 8% Notes 27
Rich Pharma Raises Funds through Private Placement of 8% Notes Due 2016 28
Rich Pharma Raises Funds through Private Placement of 8% Notes Due 2016 29
Rich Pharma Raises USD0.1 Million in Private Placement of 8% Notes Due 2016 30
Rich Pharma Raises Funds in Private Placement of 8% Notes 31
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 32
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 33
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 34
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 35
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 36
Rich Pharma Raises Funds in Private Placement of Notes Due 2015 37
Rich Pharma Raises USD0.5 Million in Private Placement of Notes 38
Rich Pharma Raises USD0.4 Million in Private Placement of Notes 39
Rich Pharmaceuticals Inc, Key Competitors 40
Rich Pharmaceuticals Inc, Key Employees 41

List of Figures
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Rich Pharmaceuticals Inc (RCHA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Petrobras Argentina SA:企業の戦略的SWOT分析
    Petrobras Argentina SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Sumitomo Dainippon Pharma Co Ltd (4506):製薬・医療:M&Aディール及び事業提携情報
    Summary Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, …
  • Oil India Ltd (OIL):企業の財務・戦略的SWOT分析
    Oil India Ltd (OIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Scynexis Inc (SCYX):企業の財務・戦略的SWOT分析
    Summary Scynexis Inc (Scynexis) is a pharmaceutical company that discovers, develops and commercializes novel anti-infective for various therapeutic needs. The company offers pipeline products such as SCY-078, is used for invasive fungal infections; SCY-635, is used for the treatment of Hepatitis C …
  • McBride plc (MCB):企業の財務・戦略的SWOT分析
    McBride plc (MCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Robert Half International Inc. (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc. (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Fraser & Neave Holdings Bhd:企業の戦略・SWOT・財務情報
    Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report Summary Fraser & Neave Holdings Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • AB Science SA (AB):製薬・医療:M&Aディール及び事業提携情報
    Summary AB Science SA (ABS) is a pharmaceutical company focused on discovery, development, and commercialization of protein kinase inhibitors. The company's lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, …
  • Nakheel:企業の戦略・SWOT・財務情報
    Nakheel - Strategy, SWOT and Corporate Finance Report Summary Nakheel - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Lansforsakringar AB:企業の戦略・SWOT・財務分析
    Lansforsakringar AB - Strategy, SWOT and Corporate Finance Report Summary Lansforsakringar AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Pelago Bioscience AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Pelago Bioscience AB (Pelago Bioscience) is a developer of patented cellular thermal shift assay for use in determination and quantification of drug–target interactions. The company utilizes patented CETSA technology which enables direct, in situ physiologically relevant measurements of targ …
  • Orange Polska S.A.:企業の戦略・SWOT・財務情報
    Orange Polska S.A. - Strategy, SWOT and Corporate Finance Report Summary Orange Polska S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Twenty-First Century Fox Inc. (FOXA):企業の財務・戦略的SWOT分析
    Twenty-First Century Fox Inc. (FOXA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Xylem Inc (XYL):企業の財務・戦略的SWOT分析
    Xylem Inc (XYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Panoptes Pharma GesmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Panoptes Pharma GesmbH (Panoptes Pharma) is a biotech company that develops small molecule based therapies to treat severe eye diseases. The company also develops products in the therapeutic areas of uveitis, viral conjunctivitis, and further indications. It concentrates on a new treatment f …
  • Hewlett Packard Enterprise Company:企業の戦略・SWOT・財務情報
    Hewlett Packard Enterprise Company - Strategy, SWOT and Corporate Finance Report Summary Hewlett Packard Enterprise Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Liebherr-International AG:企業の戦略・SWOT・財務分析
    Liebherr-International AG - Strategy, SWOT and Corporate Finance Report Summary Liebherr-International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • UbiVac LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary UbiVac LLC (UbiVac) is a clinical stage immuno-oncology companythat offers immunotherapeutic products. The company offers research and development of therapeutic vaccines for the treatment of cancer and infectious diseases. Its pipeline product includes DPV-001, a DC-targeted complex vaccine …
  • OraSolv AB (OS):企業の財務・戦略的SWOT分析
    OraSolv AB (OS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Emirates Flight Catering:企業の戦略・SWOT・財務分析
    Emirates Flight Catering - Strategy, SWOT and Corporate Finance Report Summary Emirates Flight Catering - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆